NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
Actuate Therapeutics Inc.
Kyowa Kirin Co., Ltd.
Sumitomo Pharma America, Inc.
Endocyte
Eli Lilly and Company
Novo Nordisk A/S
Janssen Research & Development, LLC
Tesaro, Inc.
Xian-Janssen Pharmaceutical Ltd.
Janssen Research & Development, LLC
Amgen
Azaya Therapeutics, Inc.
Endocyte
Sanofi